Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Research Council of Canada Industrial Research Assistance Program (IRAP) has granted funding to partially assist DelMar Pharma in research associated with the molecular mechanism of anti-cancer therapy, VAL-083.
Subscribe to our email newsletter
The company intends to conduct the research work in cooperation with the University of British Columbia and the BC Cancer Agency.
The data from preclinical trials showed anti-cancer activity with VAL-083, a small molecule chemotherapeutic.
DelMar Pharma has submitted an investigational new drug (IND) application with the US Food & Drug Administration (FDA) to conduct clinical trials for VAL-083 in patients with glioblastoma multiforme (GBM).
DelMar Pharma president and CEO Jeffrey Bacha said to develop and commercialize VAL-083 they are leveraging previous human clinical trial data demonstrating activity in GBM, including in patients having failed prior therapies.
"Based on these data, we believe that VAL-083 has potential to offer a new treatment option to physicians and patients," Bacha said.